RECRUITING

F 18 T807 Tau PET Imaging of Alzheimer's Disease

Talk to us

Conditions

Alzheimer DiseaseDementiaTauopathiesBrain DiseasesCentral Nervous System DiseasesMild Cognitive ImpairmentNervous System DiseasesNeurodegenerative Disease

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils.

Official Title

F 18 T807 Tau PET Imaging of Alzheimer's Disease [IND# 123119] Protocol A

Quick Facts

Study Start:2014-10-23
Study Completion:2024-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02414347

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Male or female participants, at least 18 years of age.
  2. 2. Cognitively normal, or with mild dementia, as assessed clinically
  3. 3. Participant is able and willing to undergo testing (MRI or CT, PET, radioactive tracer injection, LP; for those unable to undergo an MRI, CT will be used to generate regions-of-interest).
  4. 4. Pre-menopausal women will undergo a urine pregnancy test within 24 hours of drug administration.
  1. 1. Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants with severe chronic back pain might not be able to lie still during the scanning procedures).
  2. 2. Is deemed likely unable to perform the imaging procedures for any reason.
  3. 3. Has a high risk for Torsades de Pointes or is taking medications known to prolong QT interval.
  4. 4. Has hypersensitivity to F 18 T807 or any of its excipients.
  5. 5. Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate.
  6. 6. Severe claustrophobia.
  7. 7. Currently pregnant or breast-feeding.
  8. 8. For those electing to undergo the optional lumbar puncture: currently on anticoagulant of any form -

Contacts and Locations

Study Contact

Kelley M Jackson, BA
CONTACT
314 362-1558
kelleyj@wustl.edu

Principal Investigator

Tammie Benzinger, MD, PhD
PRINCIPAL_INVESTIGATOR
Washington University School of Medicine

Study Locations (Sites)

Washington University School of Medicine
Saint Louis, Missouri, 63110
United States

Collaborators and Investigators

Sponsor: Tammie L. S. Benzinger, MD, PhD

  • Tammie Benzinger, MD, PhD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2014-10-23
Study Completion Date2024-12

Study Record Updates

Study Start Date2014-10-23
Study Completion Date2024-12

Terms related to this study

Keywords Provided by Researchers

  • Dementia
  • Tauopathies
  • Brain Diseases
  • Central Nervous System Diseases
  • Mild Cognitive Impairment
  • Nervous System Diseases
  • Neurodegenerative Disease

Additional Relevant MeSH Terms

  • Alzheimer Disease